$2.86
4.76% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US73730P1084
Symbol
PSTX
Sector
Industry

Poseida Therapeutics Inc Stock price

$2.86
+0.45 18.67% 1M
-0.11 3.70% 6M
-0.50 14.88% YTD
+0.13 4.76% 1Y
-4.32 60.17% 3Y
-12.49 81.37% 5Y
-12.49 81.37% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.13 4.76%
ISIN
US73730P1084
Symbol
PSTX
Sector
Industry

Key metrics

Market capitalization $278.75m
Enterprise Value $130.63m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.87
P/S ratio (TTM) P/S ratio 1.85
P/B ratio (TTM) P/B ratio 3.19
Revenue growth (TTM) Revenue growth 203.18%
Revenue (TTM) Revenue $150.86m
EBIT (operating result TTM) EBIT $-62.50m
Free Cash Flow (TTM) Free Cash Flow $-17.13m
Cash position $230.85m
EPS (TTM) EPS $-0.63
P/E forward negative
P/S forward 1.89
EV/Sales forward 0.89
Short interest 6.26%
Show more

Is Poseida Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Poseida Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Poseida Therapeutics Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Poseida Therapeutics Inc forecast:

Buy
100%

Financial data from Poseida Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
151 151
203% 203%
100%
- Direct Costs 5.47 5.47
1% 1%
4%
145 145
229% 229%
96%
- Selling and Administrative Expenses 35 35
9% 9%
24%
- Research and Development Expense 167 167
17% 17%
111%
-57 -57
57% 57%
-38%
- Depreciation and Amortization 5.47 5.47
1% 1%
4%
EBIT (Operating Income) EBIT -63 -63
54% 54%
-41%
Net Profit -61 -61
54% 54%
-40%

In millions USD.

Don't miss a Thing! We will send you all news about Poseida Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Poseida Therapeutics Inc Stock News

Positive
Reuters
about 6 hours ago
Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing, for a total equity value of $1 billion, the Swiss company said on Tuesday.
Neutral
PRNewsWire
about 6 hours ago
Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and ge...
Neutral
PRNewsWire
12 days ago
Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1 Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic TSCM-rich CAR-T for both autoimmune diseases and oncology Advancing innovative strategies to overcome the uni...
More Poseida Therapeutics Inc News

Company Profile

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.

Head office United States
CEO Kristin Yarema
Employees 330
Founded 2014
Website www.poseida.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today